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Summary
In the therapy of metastatic melanoma, prior to 2011 the only approved treatment 
option were dacarbazine and interleukin-2, with a small percentage of patients with good 
response; no study involving these agents had shown an improvement in overall survi-
val. Researches in the last decades have contributed to a better understanding of me-
lanoma. The discovery that BRAF is a driver oncogene in cancer and complementary 
improvements in our understanding of the immune system have resulted in new targeted 
and immune-therapies for metastatic melanoma. Targeted therapies can achieve impre-
ssive clinical results in large number of patients, but the resistance to the therapy is often 
present. Immune therapy can achieve long-term remission and cures, yet in a smaller 
proportion of patients, and we still have no biomarkers to predict which patients will res-
pond. Nevertheless, melanoma has led the evolution of cancer treatment from relatively 
non-specific cytotoxic agents to highly selective therapies, which offer an improvement 
in the outcome for melanoma patients. Still, many open questions remain: how to avoid 
resistance to therapy; how to find biomakers to predict answer to therapy; and how to find 
the optimal treatment options for patients who relapse or do not respond.
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INTRODUCTION
Metastatic melanoma has a poor prognosis. The median survival for pa-
tients with stage IV melanoma ranging from 8 to 18 months after diagnosis, 
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depending on the substage. Few patients have a response to systemic thera-
pies [1].
The only chemotherapeutic agent approved by the Food and Drug Ad-
ministration for the treatment of metastatic melanoma for many years was 
dacarbazine.  In phase 3 studies, dacarbazine was associated with a response 
rate of 7 to 12% and a median overall survival of 5.6 to 7.8 months after the 
initiation of treatment. Higher response rates can be achieved with combi-
nation chemotherapy, but these combinations have not resulted in improved 
rates of overall survival. Some other agents were used  to treat metastatic 
melanoma- temozolomide, fotemustine, carboplatin, paclitaxel, and interleu-
kin-2 and demonstrated limited efficacy, and no study involving these agents 
had shown an improvement in overall survival [1-5].
BRAF INHIBITOR
The era of targeted therapy in melanoma began with the identification 
of driver mutations in the serine threonine kinase BRAF. Approximately 40-
60% of melanomas harbor activating (V600) mutations in the serine–threo-
nine protein kinase B-RAF (BRAF). Melanomas carrying a BRAF V600E mu-
tation constitutively activate the mitogen-activated protein kinase (MAPK) 
pathway, promoting cell proliferation and preventing apoptosis [6].
Vemurafenib was developed as a potent kinase inhibitor with specificity 
for the BRAF V600E mutation within cancer cells. It has marked antitumor 
effects against melanoma cell lines with the BRAF V600E mutation but not 
against cells with wild-type BRAF [7].
The oral BRAF inhibitor vemurafenib frequently produced tumor regre-
ssions in patients with BRAF V600–mutant metastatic melanoma. A phase 1 
trial established the maximum tolerated dose to be 960 mg twice daily and 
showed frequent tumor responses [8].
A phase 2 trial involving patients who had received previous treatment 
for melanoma with the BRAF V600E mutation showed a confirmed response 
rate of 53%, with a median duration of response of 6.7 months [9].
A phase 3 randomized clinical trial comparing vemurafenib with dacar-
bazine in 675 patients with previously untreated, metastatic melanoma with 
the BRAF V600E mutation. Patients were randomly assigned to receive either 
vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per squ-
are meter of body-surface area intravenously every 3 weeks). At 6 months, 
overall survival was 84% (95% confidence interval [CI], 78 to 89) in the ve-
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murafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group. In the 
interim analysis for overall survival and final analysis for progression-free 
survival, vemurafenib was associated with a relative reduction of 63% in the 
risk of death and of 74% in the risk of either death or disease progression, as 
compared with dacarbazine (P<0.001 for both comparisons). Response rates 
were 48% for vemurafenib and 5% for dacarbazine. Benefit was seen in all 
subgroups of patients who were included in the analysis, including patients 
with stage M1c disease or an elevated lactate dehydrogenase level, both of 
which are associated with particularly poor prognoses [10].
Similar to the first selective serine/threonine-protein kinase B-raf inhibi-
tor vemurafenib, another selective inhibitor dabrafenib is highly efficacious 
in melanoma patients with BRAF V600E mutations, with response rates of 
approximately 50% and progression-free survival of 6 months. There is data 
to suggest that dabrafenib not only shows activity in V600E-mutated melano-
ma, but also in non-V600E BRAF mutated disease such as V600K. Dabrafenib, 
an inhibitor of mutated BRAF, has clinical activity with a manageable safety 
profile in studies of phase 1 and 2 in patients with BRAF(V600) mutated me-
tastatic melanoma. In fase 3 randomised controlled trial dabrafenib (187 pa-
tients) or dacarbazine (63 patients). Median progression-free survival was 5,1 
months for dabrafenib and 2,7 months for dacarbazine, with a hazard ratio 
(HR) of 0,30 (95% CI 0·18-0·51; p<0·0001) [11].
MEK INHIBITOR
As was already told, the most commonly observed BRAF mutation, 
V600E, and the next most common, V600K, account for 95% of the BRAF mu-
tations found in all patients with cancer. Activated BRAF phosphorylates and 
activates MEK proteins (MEK1 and MEK2), which then activate downstream 
MAP kinases. The MAP kinase pathway is known to regulate proliferation 
and survival of tumor cells in many cancers.9 In preclinical models of hu-
man melanoma, selective BRAF and MEK inhibitors have inhibited growth 
and induced cell death in tumors bearing BRAF mutations [7].
Trametinib is an orally available, small-molecule, selective inhibitor of 
MEK1 and MEK2. In the phase 3 open-label trial, 322 patients who had meta-
static melanoma with a V600E or V600K BRAF mutation were assigned to re-
ceive either trametinib, an oral selective MEK inhibitor, or chemotherapy in a 
2:1 ratio. Patients received trametinib (2 mg orally) once daily or intravenous 
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dacarbazine (1000 mg per square meter of body-surface area) or paclitaxel 
(175 mg per square meter) every 3 weeks. Median progression-free survival 
was 4.8 months in the trametinib group and 1.5 months in the chemotherapy 
group (hazard ratio for disease progression or death in the trametinib gro-
up, 0.45; 95% confidence interval [CI], 0.33 to 0.63; P<0.001). At 6 months, the 
rate of overall survival was 81% in the trametinib group and 67% in the che-
motherapy group despite crossover (hazard ratio for death, 0.54; 95% CI, 0.32 
to 0.92; P=0.01). Rash, diarrhea, and peripheral edema were the most common 
toxic effects in the trametinib group and were managed with dose interrupti-
on and dose reduction; asymptomatic and reversible reduction in the cardiac 
ejection fraction and ocular toxic effects occurred infrequently. Secondary 
skin neoplasms were not observed. Trametinib, as compared with chemothe-
rapy, improved rates of progression-free and overall survival among patients 
who had metastatic melanoma with a BRAF V600E or V600K mutation [12].
BRAF + MEK INHIBITOR
As with most targeted therapies that block a driver oncogene, cancer cells 
can develop acquired resistance.  Resistance to BRAF inhibitors in melanoma 
is complex and mediated through multiple mechanisms with heterogeneous 
patterns of progression observed. The currently available data have indica-
ted that the MAPK pathway is reactivated in resistant tumors. Some initial 
investigations suggest that reactivation of the MAPK pathway through the 
emergence of truncated hyperactive forms of BRAF, [13] secondary muta-
tions in NRAS (the neuroblastoma RAS viral oncogene homologue) [14] or 
MEK (MAP kinase kinase), [15] up-regulation of COT (also known as TPL2 
or MAP3K8), [16] or activation of alternative survival pathways induced by 
in-creased expression of receptor tyrosine kinases but not by secondary po-
int mutations in BRAF32,35 are all mechanisms of resistance [17].
In vitro, MAPK signalling recovers rapidly following BRAF inhibition, in 
part through the relief of feedback inhibition in the pathway and an incre-
ased sensitivity to growth factors such as epidermal growth factor (EGF), 
neuregulin (NRG-1), hepatocyte growth factor (HGF) and fibroblasts growth 
factor (FGF). [17] In this context, reactivation of MAPK signalling following 
BRAF inhibition is important for therapeutic escape with increased levels of 
cell death and tumour regression being seen when BRAF and MEK are co-
targeted [18-19]. 
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Clinical trials have confirmed these preclinical observations with the 
BRAF/MEK inhibitor combination (dabrafenib plus trametinib) showing 
an increased PFS compared with BRAF inhibitor alone. In open-label study 
(Flaherty 2012.)162 patients were randomly assigned to receive combination 
therapy with dabrafenib (150 mg) plus trametinib (1 or 2 mg) or dabrafenib 
monotherapy. The combination therapy 150/2 (full-dose) group had signi-
ficantly longer progression-free survival than did the monotherapy group 
(hazard ratio, 0.39; 95% CI, 0.25 to 0.62; P<0.001). The percentage of patients 
who were alive and progression-free at 1 year was also substantially higher 
(41% vs. 9%, P<0.001). The extent of tumor regression was also greater in the 
combination 150/2 group, with an objective response rate of 76%, as compa-
red with 54% with monotherapy (P = 0.03). In addition, the median duration 
of response was substantially improved with combination therapy, as com-
pared with dabrafenib monotherapy (10.5 months vs. 5.6 months) [20].
Another BRAF/MEK inhibitor combination vemurafenib+cobimetinib 
also appears promising, with newly released data from the BRIM-7 trial de-
monstrating an 87% confirmed response rate by RECIST and a median PFS 
of 13.7 months [21].
In treating BRAF-mutant melanoma a lot of progress has been made in 
developing oncogene directed therapies. With BRAf inhibitor response has 
been reported in about 25% and 50% of patients, and the median duration 
of response is about 6–7 months.10 Combination therapy with BRAF and 
MEK inhibitors results in an objective response rate of 76% and extends pro-
gression-free survival (PFS), but most patients develop resistance to these 
inhibitors. [20]. The major problem that limits the long-term responsiveness 
of the patients is resistance to these drugs. Current strategies to improve the 
durability of response are now focused on the development of personali-
zed combination therapy strategies, the majority of which point upon the 
suppression of adaptive MAPK and PI3K/AKT signaling. At this time, the 
relationship between the genetic prolife of the tumor and patterns of adap-
tive signaling are not well understood. Better assays and biomarkers will be 
needed to explore the early treatment responses. The analysis of circulating 
tumor cells, circulating tumor DNA and proteomic methods are the strategi-
es that are exploring [22].
56
Rad 520. Medical Sciences, 40 (2014) : 51-60
J. Marić Brozić, N. Đaković: Personalised therapy for melanoma
CTLA-4 IMMUNOTHERAPY
Cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) is an immune 
check-point molecule that down-regulates pathways of T-cell activation.  Ipi-
limumab, is  a fully human monoclonal antibody (IgG1) that blocks CTLA-4 
on lymphocytes to promote antitumor immunity. [23] Ipilimumab has re-
cently been associated with superior overall survival, with median overall 
survival of 10.1 months among previously treated patients and 11.2 months 
among previously untreated patients [24-25].
In the study leading to approval of ipilimumab, patients with unresecta-
ble stage III or IV melanoma, whose disease had progressed while they were 
receiving therapy for metastatic disease, were randomly assigned, in a 3:1:1 
ratio, to receive ipilimumab plus gp100 (403 patients), ipilimumab alone 
(137), or gp100 alone (136). Ipilimumab, at a dose of 3 mg per kilogram of 
body weight, was administered with or without gp100 every 3 weeks for 
up to four treatments. The results showed median overall survival was 10.0 
months among patients receiving ipilimumab plus gp100, as compared with 
6.4 months among patients receiving gp100 alone (hazard ratio for death, 
0.68; P<0.001). The median overall survival with ipilimumab alone was 10.1 
months (hazard ratio for death in the comparison with gp100 alone, 0.66; 
P=0.003). No difference in overall survival was detected between the ipilimu-
mab groups (hazard ratio with ipilimumab plus gp100, 1.04; P=0.76). Grade 3 
or 4 immune-related adverse events occurred in 10 to 15% of patients treated 
with ipilimumab and in 3% treated with gp100 alone. There were 14 deaths 
related to the study drugs (2.1%), and 7 were associated with immune-related 
adverse events [24].
In the study with previously untreated metastatic melanoma, 502 pati-
ents were assigned to ipilimumab (10 mg per kilogram) plus dacarbazine 
(850 mg per square meter of body-surface area) or dacarbazine (850 mg per 
square meter) plus placebo, given at weeks 1, 4, 7, and 10, followed by dacar-
bazine alone every 3 weeks through week 22. Overall survival was signifi-
cantly longer in the group receiving ipilimumab plus dacarbazine than in 
the group receiving dacarbazine plus placebo (11.2 months vs. 9.1 months, 
with higher survival rates in the ipilimumab-dacarbazine group at 1 year 
(47.3% vs. 36.3%), 2 years (28.5% vs. 17.9%), and 3 years (20.8% vs. 12.2%) (ha-
zard ratio for death, 0.72; P<0.001). Grade 3 or 4 adverse events occurred in 
56.3% of patients treated with ipilimumab plus dacarbazine, as compared 
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with 27.5% treated with dacarbazine and placebo (P<0.001). No drug-related 
deaths or gastrointestinal perforations occurred in the ipilimumab-dacarba-
zine group [25].
However, the majority of patients do not have a response to anti-CTLA4 
antibody therapy and still need effective therapeutic options.
ANTI  PD-1
In patients with ipilimumab-refractory melanoma the distinct mechani-
sm of action of anti-programmed-death-receptor-1 (PD-1) antibodies, might 
have activity [26].
PD-1 is expressed on antigen-stimulated T cells and induces downstream 
signalling that inhibits T-cell proliferation, cytokine release, and cytotoxi-
city. Melanoma and many other tumors suppress cytotoxic T-cell activity by 
expressing PD-1 ligand (PD-L1) on the cell surface. Anti-PD-1 and PD-L1 an-
tibodies can reverse this T-cell suppression and induce long-lasting antitu-
mour responses in patients with advanced solid tumors, including advanced 
melanoma [26].
Pembrolizumab (MK-3475, previously known as lambrolizumab) is a 
highly selective, humanised monoclonal IgG4-kappa isotype antibody aga-
inst PD-1 that has shown strong clinical activity with an acceptable safety 
profile. In phase I trial pembrolizumab at a dose of 2 mg/kg or 10 mg/kg 
every 3 weeks might be an efective treatment in patients who progresed to 
ipilimumab [27].
CONCLUSION
In melanoma we testify the evolution of cancer treatment from nonspeci-
fic cytotoxic agents to highly selective therapies. Recent advances in treatment 
of melanoma: the mitogen-activated protein kinase pathway inhibitors ve-
murafenib, dabrafenib, trametinib, anti-cytotoxic T-lymphocyte-associated-
antigen-4 (CTLA-4) antibody ipilimumab, anti PD-1 pembrolizumab offer 
the patients improvements in outcomes. But still some challenges remain: 
how to avoid resistace to therapy, find the biomakers to predict answer to 
therapy and find the optimal treatment options for patients who relapse or 
do not respond.
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U liječenju metastatskog melanoma prije 2011. godine, jedina dva odobrena lijeka 
bili su dakarbazin i interleukin 2., s malim postotkom bolesnika u kojih je zabilježen do-
bar odgovor. Niti jedna studija s tim lijekovima nije pokazala učinak na ukupno preživ-
ljenje. Istraživanja posljednjih desetljeća pridonijela su boljem razumijevanju melano-
ma. Otkriće BRAF mutacije kao važnog onkogena u melanoma i istovremeno razvijanje 
lijekova s djelovanjem na imunološki sustav, rezultirali su novim ciljanim i imunološkim 
terapijama za liječenje metastatskog melanoma. Ciljana terapija postiže impresivne kli-
ničke rezultate u velikom broju bolesnika, ali se često razvija rezistencija na terapiju. 
Imunološka terapija postiže dugotrajnu remisiju, ali u manjem postotku pacijenata, a još 
uvijek nemamo biomarkere za predviđanje koji su to pacijenti koji će reagirati. Ipak, u 
terapiji melanom svjedočimo evoluciji u liječenju raka od relativno nespecifičnih cito-
toksičnih lijekova do vrlo selektivne terapije koja nudi poboljšanje u ishodu liječenja 
za pacijente s melanomom. Ipak, puno je još otvorenih pitanja: kako izbjeći pojavu 
rezistencije na liječenje, naći biomarkere kao prediktore dobrog odgovora na terapiju i 
utvrditi optimalan način liječenja za bolesnike nakon progresije i za one koji ne reagi-
raju na ove terapije.
Ključne riječi: metastatski melanom; imunoterapija; ciljana terapija.
Corresponding author:
Nikola Đaković
E-mail: ndakovic@mef.hr
